Company intelligence / Profile preview

CBC Group

Ownership: Private
Development stage: Other

Overview

CBC Group is Asia’s largest healthcare-dedicated asset management and private equity firm. It focuses on platform-building and buyouts across pharmaceutical, biotech, medical technology, and healthcare services sectors. The group is known for acquiring mature assets from global pharma companies—such as UCB’s neurology/allergy business in China—and building leading regional platforms like Hasten Biopharmaceutical. Its unique “investor–operator” approach has enabled it to drive operational improvements and international expansion of its portfolio companies.

Industry: Investors

Partnerships

Mubadala Investment CompanyShunxi FundBSCOMCBeijing E-Town International Investment & Development Co., Ltd.

Beyond the preview

Go deeper on CBC Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBC Group.

Explore the full profile